This month's episode dives into progressive fibrosing ILD, previously a disadvantaged set of patients who have a progressive ILD but as they weren't specifically UIP they were not entitled to antifibrotic treatment. So thank goodness for the INBUILD trial back in 2020 and it's extension and NICE technological appraisal for injecting pragmastism not only in to the types of patients now referrable for antifibrotics, but also the referral criteria. This has moved away from FVC and towards radiological classification and gas transfer which we all know are useful parameters of parenchymal health. We also talk about post COVID fibrosis, anti-reflux medication and anti-cough medication. I am joined by two regional experts in the field, Dr Chris Huntley and Dr Gareth Walters.
References are below:
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials PMID: 21571362
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis DOI: 10.1056/NEJMoa1402582
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis DOI: 10.1056/NEJMoa1402584
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
DOI: 10.1056/NEJMoa1103690
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
PMID: 33798455
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
DOI: 10.1056/NEJMoa1908681
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
PMID: 35050837
Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PMID: 34795926
Post COVID PFT and CT systematic review: PMID: 35642193